Direct inhibition of CSE1L by gene knockdown or inhibition of HDAC1/2 by mocetinostat treatment activated RB-DREAM and induced toxicity in p53 WT but not p53 mutant NSCLC cells. This evidence concerns the gene TP53 and non-small cell lung carcinoma.